title: [Potential of PET in the diagnosis and the assessment of treatment effectiveness in progressive malignant glioma].
abstract: Examination including MRI (CT), PET with sodium 11C-butyrate (11C-SB) and 18fluorodeoxyglucose (18F-FDG) was carried out in 59 patients with continuing growth of malignant glioma. It was established that 11C-SB-PET is characterized by high sensitivity (94.1%) in detecting continuing growth as well as to differentiating it from necrosis. Our data were instrumental in prognosis and assaying metabolic levels in tumor (T/NT ratios) which are regarded as indices of accumulation (IA) of 18F-FDG-PET (FDG-IA) prior to conservative treatment. There were a direct correlation between metabolic activity of neoplasms and an inverse one with FDG-IA (r=-0.24).
authors: N A
authors: NA
authors: Kostenikov
authors: L A
authors: LA
authors: Tiushin
authors: N P
authors: NP
authors: Fadeev
authors: A V
authors: AV
authors: Kartashev
authors: E M
authors: EM
authors: Zykov
authors: M Iu
authors: MIu
authors: Golovtsova
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D002250:Carbon Radioisotopes; D005260:Female; D019788:Fluorodeoxyglucose F18; D005910:Glioma / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D002250:Carbon Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18